Cargando…
1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454357/ http://dx.doi.org/10.1016/j.annonc.2021.08.1582 |
| _version_ | 1784570472333049856 |
|---|---|
| author | Zemel, M. Kian, W. Kestenbaum, E.H. Alguayn, W. Levitas, D. Sharb, A.A. Shalata, W. Rouvinov, K. Nesher, L. Yakobson, A. |
| author_facet | Zemel, M. Kian, W. Kestenbaum, E.H. Alguayn, W. Levitas, D. Sharb, A.A. Shalata, W. Rouvinov, K. Nesher, L. Yakobson, A. |
| author_sort | Zemel, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8454357 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84543572021-09-21 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options Zemel, M. Kian, W. Kestenbaum, E.H. Alguayn, W. Levitas, D. Sharb, A.A. Shalata, W. Rouvinov, K. Nesher, L. Yakobson, A. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-09 2021-09-21 /pmc/articles/PMC8454357/ http://dx.doi.org/10.1016/j.annonc.2021.08.1582 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Zemel, M. Kian, W. Kestenbaum, E.H. Alguayn, W. Levitas, D. Sharb, A.A. Shalata, W. Rouvinov, K. Nesher, L. Yakobson, A. 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| title | 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| title_full | 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| title_fullStr | 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| title_full_unstemmed | 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| title_short | 1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| title_sort | 1589p safety of the bnt162b2 mrna covid-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454357/ http://dx.doi.org/10.1016/j.annonc.2021.08.1582 |
| work_keys_str_mv | AT zemelm 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT kianw 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT kestenbaumeh 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT alguaynw 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT levitasd 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT sharbaa 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT shalataw 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT rouvinovk 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT nesherl 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions AT yakobsona 1589psafetyofthebnt162b2mrnacovid19vaccineinoncologicpatientsundergoingnumerouscancertreatmentoptions |